You are here

Using nanoparticles to deliver antibody therapy against COVID-19

COVID-19 Research Area(s): Vaccines & Treatments

Dr. Pieter Cullis, a professor in the faculty of medicine at UBC and researcher at Djavad Mowafaghian Centre for Brain Health, is receiving $237,445 from CIHR towards developing an antibody therapy for COVID-19. The study will use lipid nanoparticles to carry genetic instructions for the antibody to the liver, resulting in the secretion of antibodies that target the SARS-CoV-2 virus. Cullis predicts that this therapy, which could protect healthcare workers from infection and treat patients infected with the virus, would be a candidate for clinical testing within one year.